Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies that target the innate immune system, announces that CEO Dr. David Bearss will serve as keynote speaker at the Med Investment Forum 2025. The event will take place on May 29, 2025, at the Rotana Beach Hotel in Abu Dhabi, UAE. https://mma.prnewswire.com/media/1776980/Halia_Logo.jpg Dr. Bearss will present: “Pioneering […]

At this pivotal juncture when near-eye display technologies are rapidly advancing toward large-scale deployment,JBD, through sustained technological innovation, has succeeded in reducing the number of defective pixels in its MicroLED micro-displays from ≤100 to ≤3 per panel. This breakthrough not only signifies that MicroLED micro-displays have reached the quality-control standard of mature display technologies such

NEW YORK, NY / ACCESS Newswire / May 28, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=150634&wire=1&utm_campaign=4 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / May 28, 2025 / If you suffered a loss on your Organon & Co. (NYSE:OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=150633&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

Company prepares for the next phase of profitable growth, market expansion, and digital transformation. Industrialization and Energy Services Company (“TAQA”), a global leader in energy and industrial services, today announced that Khalid Nouh will step down from his role as Chief Executive Officer, effective 31 May 2025, as part of the company's ongoing evolution and

NEW YORK, NY / ACCESS Newswire / May 28, 2025 / If you suffered a loss on your NET Power, Inc. (NYSE:NPWR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/net-power-inc-lawsuit-submission-form?prid=150632&wire=1&utm_campaign=20 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / May 28, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=150631&wire=1&utm_campaign=9 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

(NASDAQ:TSHA), DALLAS, May 28, 2025 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 46,868,687 shares of its common

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire May 29, 2025 DALLAS, May 28, 2025 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous

(NasdaqGM:IOVA), NEW ORLEANS, May 28, 2025 (GLOBE NEWSWIRE) — ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NasdaqGM: IOVA), if they purchased the Company's securities between May 9, 2024